December 18, 2024

Uncategorized

New Releases from NCBI BookshelfLebrikizumab (Ebglyss): Indication: For the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Lebrikizumab can be used with or without topical corticosteroids: Reimbursement Recommendation [Internet].​Lebrikizumab (Ebglyss): Indication: For the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40 kg, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Lebrikizumab can be used with or without topical corticosteroids: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Ebglyss should not be reimbursed by public drug plans for the treatment of moderate

Uncategorized

New Releases from NCBI BookshelfAvapritinib (Ayvakyt): Indication: For the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL): Reimbursement Recommendation [Internet].​Avapritinib (Ayvakyt): Indication: For the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL): Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Ayvakyt be reimbursed by public drug plans for the treatment of adult patients with

Uncategorized

New Releases from NCBI BookshelfEplontersen (Wainua): Indication: For the treatment of polyneuropathy associated with stage 1 or stage 2 hereditary transthyretin amyloidosis (hATTR) in adults: Reimbursement Recommendation [Internet].​Eplontersen (Wainua): Indication: For the treatment of polyneuropathy associated with stage 1 or stage 2 hereditary transthyretin amyloidosis (hATTR) in adults: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Wainua be reimbursed by public drug plans for the treatment of polyneuropathy (PN) associated

Uncategorized

New Releases from NCBI BookshelfClindamycin Plus Benzoyl Peroxide and Adapalene (Cabtreo): Indication: For the topical treatment of acne vulgaris in patients 12 years of age and older: Reimbursement Recommendation [Internet].​Clindamycin Plus Benzoyl Peroxide and Adapalene (Cabtreo): Indication: For the topical treatment of acne vulgaris in patients 12 years of age and older: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

It is recommended that Cabtreo be reimbursed by public drug plans for the topical treatment of acne vulgaris in patients

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top